

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97, AND §1.98 PTO-1449 FORM (MODIFIED) SHEET 1 OF 2	ATTORNEY DOCKET NO. PP18521.004		SERIAL NO. 10/505,250 (PCT/US03/05017)	
	APPLICANTS: Derek O' Hagan et al.		EXAMINER: Unassigned	
	PCT FILING DATE: February 20, 2003	GROUP ART UNIT: Unassigned	CONFIRMATION NO. 7392	

U.S. PATENT DOCUMENTS							
Ex'r Initial	Ref. No.	Document No.	Date	Name	Class	Subclass	Filed
/ZL/	A1	2002/0136776A1	September 26, 2002	Fang et al.			
/ZL/	A2	5,858,410	January 12, 1999	Muller et al.			
/ZL/	A3	6,383,470	May 7, 2002	Fritzsche et al.			

FOREIGN PATENT DOCUMENTS							
Ex'r Initial	Ref. No.	Document No.	Publication Date	Country	Class	Subclass	Translation YES NO
↓ /ZL/	B1	WO 02/26209	April 4, 2002	WIPO			
	B2	WO 00/50006	August 31, 2000	WIPO			
	B3	WO 98/33487	August 6, 1998	WIPO			
	B4	WO 97/02810	January 30, 1997	WIPO			
	B5	WO 00/06123	February 10, 2000	WIPO			
	B6	WO 01/36599	May 25, 2001	WIPO			
	B7	WO 02/26212	April 4, 2002	WIPO			
	B8	WO 01/81609	November 1, 2001	WIPO			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ex'r Initial	Ref. No.	Description
/ZL/	C1	M. Briones et al., "The Preparation, Characterization, and Evaluation of Cationic Microparticles for DNA Vaccine Therapy," <i>Pharmaceutical Research</i> , 18(5):709-712 (2001).

EXAMINER'S SIGNATURE /Zachariah Lucas/	DATE CONSIDERED 10/04/2007
---	-----------------------------------

† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609.
 Line through citation if not in conformance and not considered.
 Include copy of this form in next communication to applicant.

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).

<p>IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56, §1.97, AND §1.98</p> <p>PTO-1449 FORM (MODIFIED)</p> <p>SHEET 2 OF 2</p>	<p>ATTORNEY DOCKET NO. PP18521.004</p>		<p>SERIAL NO. 10/505,250 (PCT/US03/05017)</p>	
	<p>APPLICANTS: Derek O' Hagan et al.</p>		<p>EXAMINER: Unassigned</p>	
	<p>PCT FILING DATE: February 20, 2003</p>	<p>GROUP ART UNIT: Unassigned</p>	<p>CONFIRMATION NO. 7392</p>	

/ZL/	C2	J. Kazzaz et al., "Novel Anionic Microparticles Are a Potent Adjuvant for the Induction of Cytotoxic T Lymphocytes Against Recombinant p55 Gag from HIV -1," <i>J. Controlled Release</i> , 67:347-356 (2000).
	C3	K.S. Denis-Mize et al., "Plasmid DNA Adsorbed onto Cationic Microparticles Mediates Target Gene Expression and Antigen Presentation by Dendritic Cells," <i>Gene Therapy</i> , 7:2105-2112 (2000).
	C4	H. Jeffrey et al., "The Preparation and Characterization of Poly(lactide-co-glycolide) Microparticles. II. The Entrapment of a Model Protein Using a (Water-in-Oil)-in-Water Emulsion Solvent Evaporation Technique," <i>Pharmaceutical Research</i> , 10(3):362-368 (1993).
	C5	D.T. O'Hagan et al., "Long-Term Antibody Responses in Mice Following Subcutaneous Immunization with Ovalbumin Entrapped in Biodegradable Microparticles," <i>Vaccine</i> , 11(9):965-969 (1993).
	C6	M. Singh et al., "Cationic Microparticles Are an Effective Delivery System for Immune Stimulatory CpG DNA," <i>Pharmaceutical Research</i> , 18(10):1476-1479 (2001).
	C7	M. Singh et al., "Cationic Microparticles: A Potent Delivery System for DNA Vaccines," <i>Proc. Natl Acad. Sci. USA</i> , 97(2):811-816 (2000).
	C8	M. Singh et al., "Mucosal Immunization with HIV-1 Gag DNA on Cationic Microparticles Prolongs Gene Expression and Enhances Local and Systemic Immunity," <i>Vaccine</i> , 20:594-602 (2002).
	C9	D. O'Hagan et al., "Induction of Potent Immune Responses by Cationic Microparticles with Adsorbed Human Immunodeficiency Virus DNA Vaccines," <i>J. Virol.</i> , 75(19):9037-9043 (2001).
	C10	Y.-I. Jeong et al., "Preparation of poly(DL-lactide-co-glycolide) nanoparticles without surfactant," <i>J. Appl. Polymer Sci.</i> , 80:2228-2236 (2001).
	C11	H.-J. Jeon et al., "Effect of solvent on the preparation of surfactant-free poly(DL-lactide-co-glycolide) nanoparticles and norfloxacin release characteristics," <i>Int. J. Pharm.</i> , 207:99-108 (2000).
	C12	I. Soriano et al., "Use of surfactants in polylactic acid protein microspheres," <i>Drug Develop. Indust. Pharm.</i> , 21(5):549-558 (1995).
	C13	C.-Y. Yang et al., "Encapsulating aspirin into a surfactant-free ethyl cellulose microsphere using non-toxic solvents by emulsion solvent-evaporation technique," <i>J. Microencapsulation</i> , 18(2):223-236 (2001).
/ZL/	C14	Y. Kawashima et al., "Properties of a peptide containing DL-lactide/glycolide copolymer nanospheres prepared by novel emulsion solvent diffusion methods," <i>Eur. J. Pharm.</i> , 45:41-48 (1998).

<p>EXAMINER'S SIGNATURE</p> <p>/Zachariah Lucas/</p>	<p>DATE CONSIDERED</p> <p>10/04/2007</p>
<p>† EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609. Line through citation if not in conformance and not considered. Include copy of this form in next communication to applicant.</p> <p>* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. 1.98(d).</p>	

Docket No.: PP018521.0004

AUG 16 2007

Please type a plus sign (+) inside this box. FORM PTO/SB/08

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/505,250		
		Filing Date	05/13/2005		
		First Named Inventor	Derek O'Hagan		
		Group Art Unit	1648		
		Examiner Name	Zachariah Lucas		
Sheet	1	of	1	Attorney Docket Number	PP018521.0004

Examiner Initials*	Cite No. ¹	U.S. Patent Publication		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Class/Subclass		
/Z/	1.	US2005/0107322 A1	514/44	O'Hagan et al.	05-19-2005

Examiner Signature	/Zachariah Lucas/	Date Considered	09/28/2007
-----------------------	-------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹²Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.